Physician profile
Sara Deatsman
NPI 1083976682
$807.22
in general payments reported to CMS, 2019-2025
15 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $41.60 · 2021: $34.39 · 2022: $33.51 · 2023: $29.36 · 2024: $213 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $167.01 | 2025 | |
| Exeltis, USA INC. | $101.00 | 2024-2025 | Slynd |
| Abbvie INC. | $99.32 | 2019-2022 | |
| Hologic Sales and Service, LLC | $85.66 | 2019-2023 | Coolseal Generator |
| Astellas Pharma US INC | $70.30 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $59.63 | 2019-2024 | |
| Organon LLC | $38.78 | 2025 | Nexplanon |
| Pfizer INC. | $38.61 | 2019-2024 | |
| Pacira Pharmaceuticals Incorporated | $33.09 | 2024 | Exparel |
| Amag Pharmaceuticals, INC. | $26.19 | 2019 | |
| Daiichi Sankyo INC. | $24.44 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $22.11 | 2021 | |
| Solventum Corporation | $17.75 | 2024 | Prevena |
| Neos Therapeutics, LP | $12.03 | 2019 | |
| Shire North American Group INC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Deatsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.